ADORA2A and myasthenia gravis: Using animal models of neuromuscular diseases, it became evident that fostering the A2AR-mediated reinforcement of the neuromuscular transmission may be a good therapeutic strategy to overcome the neuromuscular deficits associated with myasthenia gravis and ALS, providing the conclusion of ongoing preclinical studies and the development of novel and safer drug compounds entitled to be used in clinical trials.